RNXT - רווח למניה בשנים עשר החודשים האחרונים RenovoRx, Inc.

לוגו גרפי של RenovoRx Corp (RNXT)

RenovoRx, Inc. (RNXT) is creating a closed ecosystem of precision GI therapy with high customer loyalty. Despite physician conservatism and pressure within the medtech niche, the GURU.Markets platform displays the TTM revenue per share, where -0.31 shows the current volume of this metric. The stability of system assembly is guaranteed by established component reserves, which minimizes logistical disruptions.

RNXT רווח נקי למניה ב-12 החודשים האחרונים RenovoRx Corporation (04.07.2022 - 16.11.2026)

RNXT (RenovoRx Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

ניתוח כללי של החברה:RNXT - RenovoRx
מוצרים מיוצרים של RenovoRx Inc

The bioengineering-based innovative model of RenovoRx, Inc. (RNXT) is clearly reflected in the 12-month net income per share snapshot. This metric determines actual equity returns by excluding the impact of issuance volume. The calculation is based on dividing the final annual financial result by the total number of securities. For a company with a high proportion of employee stock option packages, this indicator is critical when assessing capital dilution. The trend of this metric allows investors to filter out market noise from systemic business growth.